A Study Evaluating the Efficacy of Fluocinonide Cream 0.1% (Vanos) in Subjects With Atopic Dermatitis
Completed · Phase 4
Conditions studied: Atopic Dermatitis
In brief
The purpose of this research study is to better understand how fluocinonide cream 0.1% (Vanos®) works when people use it to treat atopic dermatitis for just a few days.
Key facts
- Study ID
- NCT01049243
- Run by
- Wake Forest University Health Sciences
- People needed
- 20
- Starts
- 2009-03-01
- Expected to finish
- 2009-10-01
- Last updated by the study team
- 2018-08-01
Who can join
Age: 12 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Male or female with mild to severe atopic dermatitis, 12 years of age or older, that agree to participate and provide written consent (and assent if applicable)
- Have an Investigator Global Assessment of mild to severe atopic dermatitis (IGA rating of 2 - 4 in the Investigator Global Assessment (Appendix B))
- Percentage of overall body surface are of involvement (BSA) must be ≥2%
- Women of child bearing potential will be allowed to participate in the study, and these subjects will be required to use at least one form of birth control
You may not qualify if…
- Use within 4 weeks of baseline of systemic anti-inflammatory medication, which may influence study outcome, such as systemic corticosteroids
- Application or use within 2 weeks of baseline of topical corticosteroid medications or topical anti-inflammatory medication, which may influence study outcome
- Presence of a concurrent medical condition, which is determined by the investigator to potentially interfere with study outcomes or patient assessments
- Introduction of any other prescription medication, topical or systemic, for atopic dermatitis while participating in the study
- Amount of disease involvement that would require >60 gm of cream in a 1 week period
- Subjects with known allergy or sensitivity to topical Vanos™ cream or components
- Pregnant women and women who are breastfeeding are to be excluded. Women of childbearing potential will be allowed to participate in the study, and these subjects will be required to use at least one form of birth control.
Where it is running
- Wake Forest University Health Sciences — Winston-Salem, North Carolina, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.